Pinealon regulatory status
Current status of Pinealon in the United States: Unscheduled. In sport: WADA prohibited. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
What is the current status of Pinealon?
Regulatory: UnscheduledWADA: WADA prohibitedVerified: Verified Sep 30, 2026
- FDA and compounding
- Pinealon is not an FDA approved drug and is not part of any approved drug. As of the last verification date it does not appear in any FDA 503A category or on the list of withdrawn nominations, and it is not on the 503A bulks list. It is therefore outside FDA's interim policy, and a 503A pharmacy has no federal basis to compound it from bulk. It is not eligible for 503B outsourcing. Imported and research use only products are not verified for identity or purity.
- WADA
- WADA prohibited
- Access path
- Not legally available for human use in the United States: no FDA approved product and no federal basis to compound it from bulk.
- Not an FDA approved drug and not compoundable under 503A or 503B.
- Sold as a supplement in Russia; imported and research use only products are not verified for identity or purity.
Full Pinealon page: evidence, dosing in the literature, and sources
How has the status of Pinealon changed over time?
No dated regulatory event has been recorded for Pinealon. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for Pinealon and the source of each dated event.
- [1]FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list and withdrawn nominations, current as of April 22, 2026)FDA, 2026
- [2]FDA Pharmacy Compounding Advisory Committee (July 2026 meeting on peptide nominations)FDA, 2026
- [3]FDA: Compounding and the FDA, questions and answersFDA, 2026
- [4]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
- [5]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026